Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company. This acquisition represents a significant step forward in Nicox’s strategy of creating an international ophthalmic company and will significantly broaden and strengthen Nicox’s therapeutic development pipeline.
For more information, please refer to:
- Press release dated July 2, 2014: Nicox to acquire Aciex Therapeutics, Inc.
- Press release dated October 22, 2014: Nicox’s shareholders approve acquisition of Aciex Therapeutics, Inc.
- ‘Document E’ registered with the French Autorité des Marchés Financiers (AMF) on September 30, 2014 (E.14-060) (in French, available on Nicox’s website www.nicox.com in the ‘Investor Information’ / ‘Shareholder meetings’ section).